Education
About Us
Working with TipRanks
Follow Us
Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
QNRX Stock Chart & Stats
$14.60
-$0.04(-5.59%)
At close: 4:00 PM EST
$14.60
-$0.04(-5.59%)
Day’s Range― - ―
52-Week Range$5.01 - $41.80
Previous CloseN/A
Volume155.80K
Average Volume (3M)629.04K
Market Cap
$6.89M
Enterprise Value-$7.64M
Total Cash (Recent Filing)$5.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.14
Next Earnings
Mar 12, 2026EPS Estimate
-4.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.71
Shares Outstanding838,977
10 Day Avg. Volume1,633,105
30 Day Avg. Volume629,040
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.01
Enterprise Value/Market Cap-1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$70.00Price Target Upside379.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsQuoin is continuing to read-out positive data from QRX003’s 'Whole Body’ Netherton Syndrome study finding complete skin clearing in a single patient and elimination of pruritus.
FDA Approval PotentialQuoin Pharmaceuticals is developing QRX003 for treating Netherton Syndrome, a condition with no FDA approved therapies, potentially making it the first product approved for this indication.
Financial StrengthQuoin also recently completed a significant financing, raising $16.5M upfront with the potential for up to $104.5M, which reflects QRX003’s potential in treating NS.
Bears Say
Quoin Pharmaceuticals News
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $41.80 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Quoin Pharmaceuticals’s market cap is $6.89M.
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is Mar 12, 2026 which is in 83 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$6.71 earnings per share for the quarter, missing the consensus estimate of -$4.285 by -$2.425.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -4.02.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 838,977 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$6.71 in its last earnings report, missing expectations of -$4.285. Following the earnings report the stock price went down -11.192%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
QNRX Stock 12 Month Forecast
Average Price Target
$70.00
▲(379.45% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Jaguar Animal Health
―
Adial Pharmaceuticals
―
Alzamend Neuro
―
Calidi Biotherapeutics
―